Evidence map›Paper›PMID 42908280›Full record

ArticleOxidative medicine and cellular longevity2026

New Mechanistic Insights Into Nobiletin's Protective Effects Against LPS-Induced Hyperinflammatory Acute Lung Injury in Rats: Targeting miR-200, AT1R/p38 MAPK, and HMGB1/NF-κB mTOR Pathways.

Rehab Ahmed Ahmed El-Shaer, Sarah Ibrahim, Norhan Ahmed AbuoHashish, Amira K Eltokhy, Heba Bassiony Ghanem, Rowida Raafat Ibrahim, Passant Medhat Hewady, Omnia Safwat El-Deeb, Eman E Farghal, Radwa Eissa and 2 more

Abstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rehab Ahmed Ahmed El-ShaerPhysiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-8564-0722
Sarah IbrahimBasic Science Department, Al-Rayan National College of Medicine, Al Madinah Al Munawwarah, Saudi Arabia.ORCID https://orcid.org/0000-0001-9816-5556
Norhan Ahmed AbuoHashishPharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-4814-8421
Amira K EltokhyMedical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0003-0222-1846
Heba Bassiony GhanemMedical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-7987-5111
Rowida Raafat IbrahimClinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia, ju.edu.sa.ORCID https://orcid.org/0000-0002-6500-8156
Passant Medhat HewadyPhysiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-0978-7976
Omnia Safwat El-DeebClinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia, ju.edu.sa.ORCID https://orcid.org/0000-0002-8859-4223
Eman E FarghalClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-7562-055X
Radwa EissaMicrobiology and Immunology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-3330-3919
Marwa M ShalabyMicrobiology and Immunology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0001-6655-5314
Marwa Mahmoud AwadPhysiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt, tanta.edu.eg.ORCID https://orcid.org/0000-0002-9347-7101

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory lung disorders associated with high morbidity and mortality. Dysregulation of the renin-angiotensin system (RAS) and proinflammatory pathways play an indispensable role in ALI progression.

aimThis study aimed to investigate the protective potential of nobiletin (NOB) in mitigating ALI and hyperinflammatory lung injury. MATERIAL AND

methodsThe study enrolled 32 male albino rats allocated into four groups: (Control, NOB, lipopolysaccharide [LPS], and NOB + LPS groups). Rats received NOB 20 mg/kg by oral gavage for 1 week; on the seventh day, a single dose of 15 mg/kg LPS was given by intranasal instillation. After 24 h of LPS administration, plasma and lung tissue samples were analyzed for inflammatory cytokines, mitochondrial complex-I, oxidative stress markers, and molecular signaling pathways.

resultsNOB administration significantly downregulated miR-200 expression, associated with ACE2 activation and attenuated AT1R-mediated inflammatory responses. It also decreased NF-κB and p38 MAPK signaling, reducing pulmonary and systemic levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), granulocyte monocyte-colony stimulating factor (GM-CSF), and interleukin-17A (IL-17A). Additionally, NOB improved the high mobility group box 1 (HMGB1)/NF-κB/mammalian target of rapamycin (mTOR) pathway, and increased mitochondrial complex-I may be consistent with improved tissue preservation.

conclusionNOB exerts protective effects against ALI by improving inflammatory cytokine, oxidative stress, miRNA-200, mitochondrial complex-I, and ACE2, highlighting its potential as a protective candidate for ALI and hyperinflammatory-associated lung injury.

Indexed as

Acute Lung InjuryFlavonesHMGB1 ProteinMicroRNAsTOR Serine-Threonine KinasesAnimalsInflammationLipopolysaccharidesMaleNF-kappa Bp38 Mitogen-Activated Protein KinasesRatsReceptor, Angiotensin, Type 1Signal TransductionFlavonesHMGB1 ProteinLipopolysaccharidesMicroRNAsmTOR protein, ratNF-kappa Bnobiletinp38 Mitogen-Activated Protein KinasesReceptor, Angiotensin, Type 1TOR Serine-Threonine KinasesACE2/Ang1–7ALIhyperinflammationmiR-200NF-κBnobiletin

Identifiers

PMID42908280
PMCPMC13687795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.